Twelve-Year Mortality in HIV-Infected Patients Receiving Antiretroviral Therapy: The Role of Social Vulnerability. The ANRS CO8 APROCO-COPILOTE cohort

Mocroft A. , Ledergerber B. , Katlama C. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22–29.

Palella F.J. Jr. , Baker R.K. , Moorman A.C. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27–34.

Hernando V. , Perez-Cachafeiro S. , Lewden C. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012; 57: 743–751.

Lewden C. , Bouteloup V. , De Wit S. All-cause mortality in treated HIV-infected adults with CD4 >/=500/mm³ compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41: 433–445.

Antiretroviral Therapy Cohort Collaboration, Zwahlen M, Harris R, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38: 1624–1633.

Sobrino-Vegas P. , Garcia-San Miguel L. , Caro-Murillo A.M. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7: 224–230.

Sobrino-Vegas P. , Rodriguez-Urrego J. , Berenguer J. Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care. Antivir Ther 2012; 17: 1–8.

Battegay M. , Fehr J. , Fluckiger U. , Elzi L. Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother 2008; 62: 41–44.

Antinori A. , Coenen T. , Costagiola D. Late presentation of HIV infection: a consensus definition. HIV Med 2011; 12: 61–64.

Mocroft A. , Lundgren J.D. , Sabin M.L. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013; 10: e1001510.

García de Olalla P. , Knobel H. , Carmona A. , Guelar A. , Lopez-Colomes J.L. , Cayla J.A. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30: 105–110.

Lima V.D. , Geller J. , Bangsberg D.R. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007; 21: 1175–1183.

Palella F.J. Jr. , Armon C. , Buchacz K. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS). J Antimicrob Chemother 2014; 69: 2826–2834.

Taiwo B. , Barcena L. , Tressler R. Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Curr HIV/AIDS Rep 2013; 10: 21–32.

Fuster D. , Cheng D.M. , Quinn E.K. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction 2014; 109: 62–70.

DeLorenze G.N. , Weisner C. , Tsai A.L. , Satre D.D. , Quesenberry C.P. Jr. . Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program. Alcohol Clin Exp Res 2011; 35: 203–210.

Walley A.Y. , Cheng D.M. , Libman H. Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS 2008; 22: 415–420.

Benard A. , Bonnet F. , Tessier J.F. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS 2007; 21: 458–468.

Milloy M.J. , Marshall B.D. , Kerr T. Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review. AIDS 2012; 26: 1049–1063.

Uphold C.R. , Mkanta W.N. Review: use of health care services among persons living with HIV infection: state of the science and future directions. AIDS Patient Care STDS 2005; 19: 473–485.

Vanlandingham M. , Im-Em W. , Yokota F. Access to treatment and care associated with HIV infection among members of AIDS support groups in Thailand. AIDS Care 2006; 18: 637–646.

Joy R. , Druyts E.F. , Brandson E.K. Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr 2008; 47: 500–505.

Nearns J. , Baldwin J.A. , Clayton H. Social, behavioral, and health care factors associated with recent HIV testing among sexually active non-Hispanic Black Women in the United States. Womens Health Issues 2009; 19: 52–60.

Chaisson R.E. , Keruly J.C. , Moore R.D. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995; 333: 751–756.

Katz M.H. , Hsu L. , Lingo M. , Woelffer G. , Schwarcz S.K. Impact of socioeconomic status on survival with AIDS. Am J Epidemiol 1998; 148: 282–291.

Hogg R.S. , Strathdee S.A. , Craib K.J. , O'Shaughnessy M.V. , Montaner J.S. , Schechter M.T. Lower socioeconomic status and shorter survival following HIV infection. Lancet 1994; 344: 1120–1124.

Schechter M.T. , Hogg R.S. , Aylward B. , Craib K.J. , Le T.N. , Montaner J.S. Higher socioeconomic status is associated with slower progression of HIV infection independent of access to health care. J Clin Epidemiol 1994; 47: 59–67.

McFarland W. , Chen S. , Hsu L. , Schwarcz S. , Katz M. Low socioeconomic status is associated with a higher rate of death in the era of highly active antiretroviral therapy, San Francisco. J Acquir Immune Defic Syndr 2003; 33: 96–103.

Wood E. , Montaner J.S. , Chan K. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002; 16: 2065–2072.

McMahon J. , Wanke C. , Terrin N. , Skinner S. , Knox T. Poverty, hunger, education, and residential status impact survival in HIV. AIDS Behav 2011; 15: 1503–1511.

Legarth R. , Omland L.H. , Kronborg G. Educational attainment and risk of HIV infection, response to antiretroviral treatment, and mortality in HIV-infected patients. AIDS 2014; 28: 387–396.

Lewden C. , Raff F. , Cuzin L. Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiproteases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study. J Infect Dis 2002; 186: 710–714.

Piketty C. , Castiel P. , Giral P. Lack of legal income is strongly associated with an increased risk of AIDS and death in HIV-infected injecting drug users. AIDS Care 1999; 11: 429–436.

McDavid Harrison K. , Ling Q. , Song R. , Hall H.I. County-level socioeconomic status and survival after HIV diagnosis, United States. Ann Epidemiol 2008; 18: 919–927.

Bouhnik A.D. , Chesney M. , Carrieri P. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr 2002; 31 Suppl 3: S149–S153.

Huisman M. , Kunst A.E. , Bopp M. Educational inequalities in cause-specific mortality in middle-aged and older men and women in eight western European populations. Lancet 2005; 365: 493–500.

Stirbu I. , Kunst A.E. , Bopp M. Educational inequalities in avoidable mortality in Europe. J Epidemiol Community Health 2010; 64: 913–920.

CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41 RR-17: 1–19.

Sterling R.K. , Lissen E. , Clumeck N. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317–1325.

Tate J.P. , Justice A.C. , Hughes M.D. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013; 27: 563–572.

Stevens L.A. , Coresh J. , Greene T. , Levey A.S. Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473–2483.

Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385–401.

Bissell D. , Paton A. , Ritson B. ABC of alcohol. Help: referral. Br Med J (Clin Res Ed) 1982; 284: 495–497.

Justice A.C. , Holmes W. , Gifford A.L. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001; 54 Suppl 1: S77–S90.

Carrieri M.P. , Villes V. , Raff F. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). Int J Drug Policy 2007; 18: 288–295.

Protopopescu C. , Raff F. , Roux P. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother 2009; 64: 599–606.

Chesney M.A. , Ickovics J.R. , Chambers D.B. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255–266.

Therneau T.M. , Grambsch P.M. Modeling survival data: extending the cox model. New York: Springer-Verlag, 2000.

Stata Statistical Software: Release 12. College Station, TX: StataCorp LP, 2011.

Arno P.S. , Bonuck K.A. , Green J. The impact of housing status on health care utilization among persons with HIV disease. J Health Care Poor Underserved 1996; 7: 36–49.

Villes V. , Spire B. , Lewden C. The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice. Antivir Ther 2007; 12: 1067–1074.

Cook J.A. , Burke-Miller J.K. , Cohen M.H. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS 2008; 22: 1355–1363.

Green T.C. , McGowan S.K. , Yokell M.A. , Pouget E.R. , Rich J.D. HIV infection and risk of overdose: a systematic review and meta-analysis. AIDS 2012; 26: 403–417.

Engsig F.N. , Zangerle R. , Katsarou O. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis 2014; 58: 1312–1321.

Young J. , Psichogiou M. , Meyer L. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 2012; 9: e1001194.

Gupta A. , Nadkarni G. , Yang W.T. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS ONE 2011; 6: e28691.

Hoffmann C.J. , Fielding K.L. , Johnston V. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 2011; 58: 269–276.

Sullivan P. Associations of anemia, treatments for anemia, and survival in patients with human immunodeficiency virus infection. J Infect Dis 2002; 185 Suppl 2: S138–S142.

Obel N. , Omland L.H. , Kronborg G. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS ONE 2011; 6: e22698.

Carrieri M.P. , Protopopescu C. , Raff F. Low alcohol consumption as a predictor of higher CD4+ cell count in HIV-treated patients: a french paradox or a proxy of healthy behaviors? The ANRS APROCO-COPILOTE CO-08 cohort. J Acquir Immune Defic Syndr 2014; 65: e148–e150.